Dasatinib Drugs Market, By Type (20 mg, 50 mg, and 70 mg), By Indication (Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023

Code : CMI5963

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Dasatinib Drugs MarketSize and Trends

The global dasatinib drugs market size is projected to reach US$ 2,198.7 Mn by 2030, from US$ 1,465.0 million in 2023, growing at a CAGR of 6% during the forecast period 2023-2030. Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It is also used to treat Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults and children.

Dasatinib Drugs Market Trends

Rising adoption of targeted therapies: The trend towards targeted therapies in oncology has significantly impacted the dasatinib drugs market. Dasatinib belongs to a class of targeted therapies known as tyrosine kinase inhibitors (TKIs), which specifically inhibit the activity of specific proteins involved in cancer growth. As targeted therapies continue to gain acceptance and demonstrate favorable clinical outcomes, the demand for dasatinib and other TKIs is expected to increase.
Shift towards precision medicine: Precision medicine involves tailoring treatments based on individual patient characteristics, including genetic and molecular profiles. Dasatinib's efficacy has been linked to specific genetic mutations and biomarkers. As precision medicine approaches gain momentum, there is a growing emphasis on identifying biomarkers and genetic alterations that can predict response to dasatinib. This trend drives the development of companion diagnostics and personalized treatment strategies.
Increased focus on combination therapies: Combination therapies involving dasatinib are gaining attention in the field of oncology. Combining dasatinib with other targeted therapies, immunotherapies, or conventional chemotherapy agents has shown potential for synergistic effects and improved treatment outcomes. Pharmaceutical companies and researchers are exploring different combinations to enhance treatment efficacy and overcome drug resistance, thereby driving the trend of combination therapies.
Emergence of biosimilars: With the expiration of patents for dasatinib, there is a growing market for biosimilar versions of the drug. Biosimilars are highly similar versions of approved biologic drugs and offer cost-effective alternatives to the reference product. As the market for biosimilars expands, it presents both challenges and opportunities for original manufacturers of dasatinib and generic/biosimilar manufacturers.